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Introduction Donation after circulatory death (DCD) pancreas transplantation has 
been shown to be an additional way to deal with donor organ shortages. The results 
of five year DCD pancreas transplantation are presented.  
Methods A retrospective, single center analysis (2011 – 2015) was performed to 
compare the results of donation after brain death (DBD) to DCD pancreas 
transplantation.  
Results During the study period, 104 pancreas transplantations (83 from DBD and 
21 from DCD) were performed. Median pancreas donor risk index (PDRI) was 1.47, 
(DBD 1.61 vs. DCD 1.35 (p=0.144)). Without the factor DCD, PDRI from DCD donors 
was significantly lower (DBD 1.61 vs DCD 0.97 (p<0.001). Donor age was the only 
donor related risk factor associated with pancreas graft survival (HR 1.06, p=0.037). 
Postoperative bleeding and kidney DGF occurred more frequently in recipients from 
DCD (p=0.006). However, DCD pancreata had a lower incidence of thrombosis. 
Kidney and pancreas graft survival were equally good in both groups. 
Conclusion Pancreas transplantation from DCD donors yields comparable results to 
DBD donors when PDRI of DCD are relatively low. Most DCD donors are younger 
donors with trauma as cause of death. These DCD pancreas grafts may be a better 
option to cope with increasing organ shortages than exploring the limits with older 
(and higher PDRI) DBD donors.  
  
Introduction 
Pancreas transplantation from donation after brain death (DBD) has been steadily 
improving over the last decades with good long-term outcome in terms of patient and 
graft survival.(1-3) Simultaneously, the number of patients and time on the waiting list  
increased in the Eurotransplant area.(4, 5) Unfortunately, suitable DBD organs 
matching this need remained stagnant.(5) Pancreatic grafts from donation after 
circulatory death (DCD) have been shown to be suitable for transplantation and may 
provide an additional organ source.(6-11)  
 
The first DCD pancreas transplantation in our center was performed in 2011.(8) In 
2015, 52% of all donor procedures in The Netherlands were DCD, and 9/20 (45%) of 
pancreas transplantations at our institute were from DCD procedures.(12)  
 
The warm ischemic period during graft procurement is generally believed to inflict a 
higher degree of ischemia reperfusion injury and subsequently post-reperfusion graft 
pancreatitis and thrombosis. This makes transplant professionals reluctant to accept 
DCD grafts for transplantation. In general, peri-pancreatic infections occur in 
approximately 35% of all pancreas transplantations, but the question is whether 
these are all clinically significant. (13, 14) However, with careful DCD donor 
selection, the detrimental effects of warm ischemia on the allograft may be limited. 
 
This study investigates whether the use of DCD pancreas donors is feasible when 
careful donor selection, indicated by the Pancreas Donor Risk Index (PDRI), is 
performed. More specifically, short term outcome (90 days patient and graft survival 
and complications, specifically post reperfusion graft pancreatitis, peri-pancreatic 
infection, bleeding, graft thrombosis) were investigated. 
 
Methods 
All consecutive primary pancreas transplantations performed at Leiden University 
Medical Center from January 2011 until December 2015 were included in this study. 
Follow up was collected until May 1st 2016. Standard SPK transplantations were 
performed using a midline incision. The kidney was first transplanted in the left iliac 
fossa, followed by the pancreas on the right anastomosed on the iliac artery and 
caval vein. Exocrine drainage was performed by duodeno-enterostomy. All patients 
received alemtuzumab induction therapy (15 mg subcutaneous on both the day of 
the transplantation and first postoperative day). Standard maintenance 
immunosuppression consisted of tacrolimus (Prograft) (twice daily 5mg based on 
trough levels 8-12 ug/l until 6 weeks, from then trough levels 5-10 ug/l) or 
cyclosporine (trough levels 150-200 ug/l until 6 weeks, from then trough levels 100-
150 ug/l) combined with mycophenolate mofetil (twice daily 500mg when tacrolimus 
was prescribed and twice daily 1000mg when cyclosporine was prescribed), with or 
without addition of steroids. Standard anticoagulant therapy after pancreas 
transplantation consisted of subcutaneous low molecular weight heparin (nadroparin) 
2850IE twice daily. If indicated prior to transplantation, therapeutic doses were 
prescribed (e.g. in case of atrial fibrillation or previous deep venous thrombosis or 
pulmonary embolisms).  
 
Data collection 
Donor, recipient and transplant related risk factors are shown in Tables 1-3. Follow 
up data included: peak serum amylase and drain fluid amylase levels during the first 
3 postoperative days, surgical and percutaneous re-interventions, patient and 
pancreas and kidney graft survival (including causes of graft failure). Pancreas graft 
failure was death censored and defined as return to exogenous insulin therapy. 
Minimal follow up was 90 days, to allow for analysis of early pancreas graft failure 
(EGF).(15) Kidney graft failure (death censored) was defined as need for renal 
replacement therapy or relisting on the kidney transplant waiting list. 
 
Analysis 
Donor warm ischemia time was calculated from the time of withdrawal of ventilatory 
support (WVS) until the start of organ cold perfusion. Functional warm ischemia time 
was considered to start when systolic blood pressure < 50 mmHg, in line with 
Eurotransplant and British Transplantation Society guidelines.(16, 17) Post 
reperfusion graft pancreatitis was defined as an increased serum amylase levels (> 
250U/L) in combination with drain fluid amylase levels (>3000U/L), not requiring 
additional interventions.(18) Peri-pancreatic infection was defined as any peri-
pancreatic infection, including abscess, infected fluid collection or hematoma, 
requiring surgical intervention or radiological, percutaneous drainage (Clavien-Dindo 
grade IIIa/b).(14, 18) All other surgical complications, such as bleeding, anastomotic 
leakage, graft thrombosis,  graft loss, and Clavien-Dindo grade III or higher were 
analysed. Other complications, such as pneumonia, post-operative wound infection 
and urinary tract infection were not included in the database. Delayed kidney graft 
function (DGF) was defined as the need for renal replacement therapy within the first 
week after transplantation. Patient and graft survival were estimated using the 
Kaplan-Meier method. 
 
Organ procurement  
Standard DCD organ procurement in The Netherlands starts with withdrawal of 
ventilatory support at the ICU. No ante-mortem interventions (heparin administration 
or femoral artery cannulation) are legally allowed in The Netherlands. Following 
cardiac arrest, a 5-minute ‘no touch’-period is mandatory and when auto resuscitation 
does not occur within this period, the declaration of death is issued. Upon arrival in 
the operating room, a rapid laparotomy is carried out. The aorta is cannulated, the 
inferior caval vein vented and pressurized infusion of ice-cold preservation solution is 
started. This marks the end of the first warm ischemic period WIT. The remaining 
procedure, as well as DBD organ procurement, is performed as described in the 
ESOT MOD learning course.(19) Of note, in both DCD and DBD procedures 
mobilization of the pancreas was performed only after cold perfusion. Procurements 
were carried out by independent procurement teams, sometimes consisting of a local 
team, as was described elsewhere.(20) All organs were cold stored on ice in 




In the five-year study period (2011 –2015), 83 DBD (76 SPK, 7 PAK) and 21 DCD 
(20 SPK, 1PAK) primary pancreas transplantations were performed. All DCD donors 
were Maastricht category III. From the 83 DBD grafts, 3 were from another country 
and all other grafts, including all 21 DCD grafts, were from The Netherlands. Our 
local team procured 31/104 (30%). Of 21 DCD grafts, 8 (38%) were procured locally, 
compared to 23/83 (28%) DBD grafts (p=0.353). Four pancreatic grafts were initially 
bladder drained with conversion to enteric drainage in a second operation in two 
cases, as described before.(21) All other grafts were anastomosed to the terminal 
ileum. Donor, recipient and transplant demographics are shown in Table 1-3. There 
was no significant difference in steroid-free immunosuppression between both 
groups (90% in DBD vs. 86% in DCD, p=0.073). Mean duration of follow up was 2.6 
years for DBD organ recipients and 2.2 years for DCD organ recipients (p=0.2). 
 
Median PDRI of all pancreata was 1.47 (0.68 – 2.48). No statistical significant 
difference in PDRI of DBD grafts compared to DCD grafts (1.61 vs. 1.35, p=0.143) 
was observed. However, if donor type was excluded from the PDRI calculation, the 
difference between DBD and DCD was significant (1.61 vs 0.97 respectively, 
p<0.001). DCD donors were significantly younger than DBD donors (27 (11 – 47) 
years vs 43 (10 – 60) years (median (range), p=0.001)). Stroke was the leading 
cause of death in DBD (65%), whereas DCD donors died from trauma or anoxia in 
66% of the cases (p=0.001). Median donor WIT of DCD grafts was 31 (15 – 45) 
minutes, median functional WIT was 27 (12 – 42) minutes. (Table 3)  
 
Graft pancreatitis and peri-pancreatic infection 
Post-reperfusion graft pancreatitis occurred in 47 patients (45%), of which 27 
resolved spontaneously without interventions. The remaining 20 recipients developed 
(infected) fluid collections that required intervention (either percutaneous or surgical 
drainage). Peri-pancreatic infection that was not preceded by post-reperfusion graft 
pancreatitis occurred in 10 patients (Table 4). There was no statistical difference in 
the incidence of graft pancreatitis between DBD and DCD graft recipients. Logistical 
regression analysis did not show an association between donor WIT with post 
reperfusion pancreatitis and peri-pancreatic infection. From 30 patients that suffered 
from peri-pancreatic infection, 2 lost their graft within 90 days due to thrombosis.  
 
Other early postoperative outcome 
Relaparotomy was required in 32/104 patients (31%). In 17 patients, a re-operation 
was required due to postoperative bleeding. This occurred significantly more frequent 
in recipient of DCD organs (11% vs. 38%, p=0.005). DBD organ recipients lost 9 
grafts (7 due to thrombosis, 1 due to bleeding and 1 due to anastomotic leakage), 
versus none of the DCD organ recipients (p=0.198). Of all 96 SPK recipients, 17 
(16%) suffered from kidney delayed graft function (DGF). Kidney DGF occurred 
significantly more frequently with kidneys from DCD donors (13% vs. 35%, p=0.043). 
There was a statistically significant association with kidney DGF and re-interventions 
for bleeding (6/17), compared to recipients with immediate kidney function who 
required fewer reinterventions (10/80, p=0.032). Prescription of steroids as part of 
initial immunosuppression was not associated with thrombosis (p=0.314) One 
recipient with a DBD SPK died during the initial hospital stay due to systemic 
inflammatory response syndrome following two exploratory laparotomies for 
anastomotic leakages. 
  
Long term outcome 
Mean duration of follow up was 2.5 years (SD 1.3 years). Kaplan Meier estimated 
patient survival after 90 days, 1 year and 2 years was 98.8%, 97.5% and 94.5% for 
DBD recipients versus 100% for DCD recipients after 2 years (p=0.268) (Fig 1). 
Kaplan Meier estimated pancreas graft survival after 90 days, 1 year and 2 years 
was 89.2%, 85.5% and 85.5% for DBD organs and 100%, 100% and 93.3%, 
respectively, for DCD organs (p=0.428) (Fig. 2). For recipients with functioning grafts 
(insulin independence) at three months (n=95), data on HbA1c levels were available 
in 81/95 (85%). Mean HbA1c was 33 mmol/mol (SD 4mmol/mol) in the DBD group 
and 32 mmol/mol (SD 5 mmol/mol) in the DCD group (p=0.45). Kaplan Meier 
estimated kidney graft survival after 90 days, 1 year and 2 years was 98.7%, 96.0% 
and 94.1% for DBD kidneys and 100%, 93.8% and 93.8% for DCD kidneys (p=0.342) 
(Fig 3). 
 
In univariate survival analysis, analyzing the complete cohort, donor age was a 
significant risk factor for pancreas graft failure (HR 1.06, 95% CI 1.00 – 1.11, 
p=0.037). Also, PAK was a significant risk factor for pancreas graft failure compared 
to SPK (Chi2 11.80, p=0.001). DCD, as stated above, and donor cause of death (Chi2 
3.51, p=0.320) were not associated with pancreas graft survival. Using a previously 
described PDRI cut-off of 1.24 (22), high PDRI was identified as a risk factor for 
pancreas graft failure (Chi2 4.61, p=0.032). Numbers were too small to analyse PDRI 




This study compares the outcome of DCD pancreas transplantation to DBD pancreas 
transplantation in a recent cohort. This study shows that pancreas transplantation 
from young (mainly low PDRI) donors, either DCD or DBD, yields good results. 
Consequently, DCD grafts with low PDRI should certainly be considered for 
transplantation. 
 
Multiple reports, as well as multiple recent meta-analyses, have shown that it is 
feasible to utilize DCD pancreata for vascularized pancreas transplantation.(6, 9-11, 
23)  Our results corroborate with these results. Even more, this study demonstrates 
that with careful donor selection, especially in terms of donor age, but also transplant 
type (SPK vs. PAK), results from DCD pancreas transplantation are comparable to 
those of DBD pancreas transplantation. DBD donors had other risk factors and were 
on average from older donors and had more frequently stroke as a cause of death. 
All DCD grafts were from The Netherlands, mostly from the western region (17/21), in 
an attempt to keep CIT as short as possible. Therefore, PDRI was not significantly 
different between DBD and DCD donors. But when the factor ‘donor type’ (DBD or 
DCD) was eliminated from the equation, the differences in PDRI were remarkable 
and showed that DCD donors with otherwise near-to-perfect characteristics were 
selected. These data indicate that DCD donors can be used for pancreas 
transplantation, especially with relatively low PDRI (in our study mean PDRI 1.35). 
The number of re-interventions (30.8%) is comparable to the number reported in 
most studies, which may be as high as 35% in pancreas transplantation.(24) In our 
opinion, and in accordance with the risk analysis in this study, DCD donors can be 
used in addition to DBD donors with more unfavorable donor characteristics.  
 
Elaborating on individual risk factors such as age, this may be explained by the fact 
that young donors tend to have leaner pancreas grafts, with smooth intravascular 
lining. The absence of excessive peri-pancreatic fat may facilitate easier back table 
procedure (with construction of the Y-graft and trimming of excess fat). We 
hypothesize that these factors may prevent early fatty necrosis with subsequent peri-
pancreatic infection and thrombosis. In terms of PDRI, a 28-year-old DCD donor 
bears a similar risk as a 41-year-old DBD donor. (7, 25) 
 
The donor WIT we report is similar to that described in the large study from the UK 
(5), but longer than the 15 – 20 minutes that have previously been mentioned in 
studies from the United States. (6, 23, 26) Again, the current study shows that, even 
with prolonged donor WITs, even up to 45 minutes (withdrawal of ventilatory support 
to cold perfusion) and, which may even be more important, prolonged periods of 
relative hypoperfusion (functional warm ischemia time up to 42 minutes) good results 
can be achieved. This has also been shown by another single center report in 2012, 
which reported donor WITs up to 110 minutes, albeit with very long agonal phase in 
at least one case. (9) Nevertheless, WIT should still be considered an important risk 
factor associated with postoperative complications such as kidney DGF. 
 
An interesting observation was the higher risk of bleeding in DCD. It could be that the 
higher bleeding percentage in DCD recipients may be related to the higher 
percentage of kidney DGF in this group and subsequently anti-factor Xa 
accumulation or uremia associated thrombopathy. In this study, no anti-factor Xa was 
determined as a measure of nadroparin accumulation, nor were blood urea levels 
post transplantation registered. Therefore, it was not possible to proof these 
interactions. The clinical data show a higher percentage of bleeding in the kidney 
DGF group. The same mechanism may explain the difference in graft thrombosis, 
although this difference was not statistically significant. In those particular cases, 
following DCD pancreas transplantation, delayed or slower kidney graft function may 
have caused anti-factor Xa accumulation and subsequently, may have played a role 
in the prevention of pancreas graft thrombosis. We realize that the 10% risk of 
complete pancreas graft thrombosis in the DBD group seems rather high. However, 
one of cases with thrombosis did not lead to graft loss and was preserved with 
function with anti-coagulant treatment. Another explanation might be the relative high 
risk pancreas grafts that are being used in The Netherlands (medium PDRI 1.61 in 
this study). (27) We do not believe that procurement, back table preparation or 
transplantation caused the difference, since all are done the same for DBD and DCD.  
 
The percentage of post-reperfusion graft pancreatitis in this study is 45%. In a review 
by Nadalin et al., post-reperfusion graft pancreatitis is thought to occur in up to 100% 
of pancreas transplantation and is usually self-limiting.(13) However, this difference 
could be explained by the definition. We arbitrarily defined post-reperfusion graft 
pancreatitis as elevated drain amylase levels in combination with elevated serum 
amylase.  Neither DCD nor the duration of donor WIT were found to be a risk factor 
for post-reperfusion pancreatitis or peri-pancreatic infection. In our series, of 48 
patients that suffered from post reperfusion graft pancreatitis, only 20 (42%) also 
suffered from peri-pancreatic infection. This is 19% of our total population, which is 
similar to data reported in 2013.(14) Furthermore, 10/30 peri-pancreatic infections 
weren’t preceded by any biochemical abnormalities. The clinical relevance of post-
reperfusion graft pancreatitis is not entirely clear (13, 18) Interestingly, there were 
slightly more peri-pancreatic infections in DBD. Possibly, this is caused by the higher 
donor age in DBD. 
 
Mid to long-term kidney, pancreas and patient survival were generally good. Although 
DCD organ recipients suffered from more postoperative bleeding and endured more 
kidney delayed graft function, this did not reflect in inferior long term outcome. All 
patients with functioning pancreas grafts at 90 days had good glycemic control and 
kidney function. Pancreas graft survival (insulin independence) was excellent, 
especially for the DCD recipients, even up to two years after transplantation. Kidney 
graft survival was also good in both groups. 
 
Several limitations apply to this study. This is a retrospective database analysis with 
possible drawbacks that are characteristic of such studies. In addition, the data 
concern a single center and there was a relatively small number of patients in the 
study. This limited our ability to perform a multivariate risk factor analysis. 
Nevertheless, this is still one of largest single center reports on DCD pancreas 
transplantation that included all consecutive DCD pancreas transplantations in our 
center.(23) There is an ongoing discussion in the pancreas transplant community 
concerning the definition of pancreas graft failure. In this study, failure was defined as 
insulin independence (death censored). We appreciate that this is a subjective 
definition, which makes comparison difficult. However, this definition reflects the 
clinical situation of this patient, which is evaluated by a clinician. HbA1c levels, both 
at any time during follow and at start of exogenous insulin levels, facilitate 
comparison between different reports. We did not report HbA1c at the start of 
exogenous insulin therapy, since almost all had failed within 90 days (and HbA1c 
would thus reflect glycemic control from prior to the transplantation). Unpublished 
data from our center indicates that graft survival depends partially on the definition of 
failure. The protocol of immunosuppression changed over the course of the study. 
We now aim to transplant our patients in a steroid free regime, with only tacrolimus 
and mycophenolate mofetil. There is no evidence that this change in protocol 
influenced our results with regards to graft survival. 
 
We did not experience a high rate of complications leading to graft loss in the DCD 
donors. These data indicate that that DCD donors can be considered for pancreas 
donation with all parameters and possible risk factors taken into account. A pancreas 
graft from a young, lean, DCD donor after trauma, with short cold ischemia time may 
in fact yield better results than pancreas grafts from older DBD donors. All those 
parameters combined, that are reflected in a low PDRI, may be a better predictor 
than just DBD or DCD. In our opinion, such low PDRI DCD donors should not be 
precluded from vascularized pancreas donation beforehand. 
 
Conclusion 
Results from carefully chosen DCD donors for pancreas transplantation yield good 
results. Other factors than merely DCD are important in predicting outcome. We 
advocate that DCD pancreata, especially those with lower PDRI (younger donors and 
trauma as cause of death) should be considered for transplantation. This study 
shows that, although DCD recipients have more postoperative bleeding and kidney 
DGF, pancreas and kidney graft survival are at least equal to that of DBD recipients. 
Hopefully, these results will convince other transplant centers to utilize pancreata 
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Table 1. Demographics of donors after brain death and donors after circulatory death 
 DBD DCD  
  n % n % p-value 
Gender     0.037 
Male 27 32% 12 57%  
Female 56 68% 9 43%  
Cause of death     <0.001 
Stroke 54 65% 5 24%  
Trauma 22 26% 7 33%  
Anoxia 3 4% 7 33%  
Other 4 5% 2 10%   
      
  Median Min - max Median Min - max   
Age 43 10 - 60 27 11 - 47 0.003 
BMI 23 17 - 29 22 18 - 29 0.329 
ICU days 2 0 - 13 3 0 - 7 0.009 
Creatinine (mg/dL) 0.64 0.35 - 4.65 0.67 0.43 - 1.13 0.523 
PDRI 1.61 0.68 - 2.48 1.35 1.03 - 2.44 0.143 
PDRI (donortype excluded) 1.61 0.68 - 2.48 0.97 0.74 - 1.75 <0.001 
* Difference measured using Chi-square for categorical and Mann-Whitney for continuous 
variables 
 
      
  
Table 2. Demographics of recipients of DBD or DCD organs  
 DBD DCD  
  n % n % p-value 
Gender     0.526 
Male 45 46% 13 62%  
Female 38 54% 8 38%  
Coronary artery disease 11 13% 3 14% >0.999 
Cerebrovascular disease 10 13% 1 5% 0.455 
Peripheral vascular disease 29 35% 8 38% 0.816 
Sensitized (PRA>5%) 17 21% 5 24% 0.771 
      
End stage renal disease (SPK 
recipients)     0.609 
Pre-emptive 36 47% 7 35%  
Hemodialysis 24 32% 8 40%  
Peritoneal dialysis 16 21% 5 25%   
      
  Median Min - max Median Min - max   
Age 43 25 - 64  43 28 - 55 >0.999 
BMI 25 17 - 35 26 17 - 34 0.625 
* Difference measured using Chi-square for categorical and Mann-Whitney for continuous 
variables 
      
  
Table 3. Demographics of transplantations of DBD or DCD organs  
 DBD  DCD   
  n % n % p-value 
Transplant type     >0.999 
SPK 76 92% 20 95%  
PAK 7 8% 1 5%  
PTA 0 0% 0 0%  
Perfusion solution     0.075 
UW 74 89% 15 71%  
HTK/Other 9 11% 6 29%  
Anticoagulant therapy     0.180 
Nadroparin 2850IE 8 9% 0 0%  
Nadroparin 5700IE 71 86% 21 100%  
Nadroparin 11400IE** 4 5% 0 0%  
Immunosuppression     0.073 
Cyclosporin + Mycophenolate 1 1% 0 0%  
Cyclosporin + Mycophenolate +     
Prednisone 2 2% 3 14%  
Tacrolimus + Mycophenolate 74 89% 18 86%  
Tacrolimus + Mycophenolate +        
Prednisone 6 7% 0 0%   
      
  Median Min - max Median Min - max   
Pancreas CIT (hr) 10 4 - 14 11 7 - 15 0.143 
Pancreas donor functional WIT 
(min) ***   27 12 – 42 n/a 
Pancreas donor WIT (min)****   31 15 - 45 n/a 
Pancreas recipient WIT (min) 26 14 - 64 25 10 - 41 0.613 
* Difference measured using Chi-square for categorical and Mann-Whitney for continuous variables 
** These patients were on anticoagulation prior to transplantation   
*** Withdrawal of ventilatory support - systolic blood pressure < 50 mmHg  
**** Withdrawal of ventilatory support - organ cold perfusion   
      
Table 4. Early (<90 days) postoperative complications after DBD and DCD 
transplantation 
 DBD DCD  
  n % n % p-value 
Thrombosis     0.282 
Complete 8 10% 0 0%  
Partial 24 29% 7 33%  
Bleeding 9 11% 8 38% 0.006 
Post reperfusion graft pancreatitis 40 48% 7 33% 0.222 
Peri-pancreatic infection 25 30% 5 24% 0.568 
Pancreas graft loss 9 11% 0 0% 0.198 
Kidney delayed graft function 10 13% 7 35% 0.041 
Patient death 1 1% 0 0% >0.999 
 
  
 
 
 
